|
WO2020188110A1
|
|
Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof
|
|
JP2020048568A
|
|
Influenza a virus neutralizing antibodies and use methods thereof
|
|
WO2021037368A1
|
|
METHODS FOR RAPID cDNA PRODUCTION AND CLONING
|
|
EP3757127A1
|
|
Deimmunized antibodies binding to alpha-4 integrin and uses thereof
|
|
AU2019276261A1
|
|
Engineering B lymphocytes by utilizing endogenous activation-induced cytidine deaminase
|
|
HK1259389A1
|
|
Neutralizing anti-influenza a virus antibodies and uses thereof
|
|
HK1247620A1
|
|
Neutralizing anti-influenza a virus antibodies and uses thereof
|
|
KR20200141917A
|
|
Novel malaria vaccines and antibodies that bind to protozoa spp.
|
|
JP2018110581A
|
|
Influenza a virus-neutralizing antibodies and uses thereof
|
|
CA3043790A1
|
|
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
WO2019024979A1
|
|
Antibodies with functional domains in the elbow region
|
|
EP3308778A1
|
|
Arginine and its use as a t cell modulator
|
|
US2018179274A1
|
|
Proteins comprising a mutated lair-1 fragment and uses thereof
|
|
EP3313435A1
|
|
Novel vaccines in prevention and treatment of malaria
|
|
EP3288975A1
|
|
Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
|
|
AU2013202396A1
|
|
Human cytomegalovirus neutralizing antibodies and use thereof
|
|
AU2013202434A1
|
|
Dengue virus neutralizing antibodies and uses thereof
|
|
AU2012203417A1
|
|
Human cytomegalovirus neutralizing antibodies and use thereof
|
|
AU2011218704A1
|
|
Monoclonal antibody production by EBV transformation of B cells
|
|
CN107417789A
|
|
Neutralize anti-influenza A virus antibody and application thereof
|
